Ameriprise’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-89,771
| Closed | -$9.15M | – | 4001 |
|
|
2023
Q2 | $9.15M | Buy |
89,771
+84,396
| +1,570% | +$7.99M | ﹤0.01% | 1849 |
|
|
2023
Q1 | $489K | Sell |
5,375
-3,641
| -40% | -$214K | ﹤0.01% | 3438 |
|
|
2022
Q4 | $343K | Buy |
9,016
+826
| +10% | +$28.4K | ﹤0.01% | 3540 |
|
|
2022
Q3 | $205K | Buy |
+8,190
| New | +$227K | ﹤0.01% | 3698 |
|
|
2021
Q4 | – | Sell |
-3,015
| Closed | -$304K | – | 4071 |
|
|
2021
Q3 | $304K | Sell |
3,015
-100,211
| -97% | -$11.7M | ﹤0.01% | 3567 |
|
|
2021
Q2 | $14.6M | Buy |
103,226
+492
| +0.5% | +$55.6K | ﹤0.01% | 1601 |
|
|
2021
Q1 | $10.2M | Buy |
102,734
+23,281
| +29% | +$2.72M | ﹤0.01% | 1865 |
|
|
2020
Q4 | $9.82M | Buy |
79,453
+18,978
| +31% | +$2.49M | ﹤0.01% | 1770 |
|
|
2020
Q3 | $5.89M | Sell |
60,475
-180,393
| -75% | -$22.5M | ﹤0.01% | 1959 |
|
|
2020
Q2 | $37.6M | Buy |
240,868
+25,897
| +12% | +$3.94M | 0.02% | 728 |
|
|
2020
Q1 | $31M | Buy |
214,971
+106,305
| +98% | +$20.5M | 0.02% | 723 |
|
|
2019
Q4 | $22.2M | Buy |
108,666
+23,255
| +27% | +$4.24M | 0.01% | 1113 |
|
|
2019
Q3 | $6.86M | Sell |
85,411
-45,475
| -35% | -$3.86M | ﹤0.01% | 1983 |
|
|
2019
Q2 | $12.3M | Buy |
130,886
+10,713
| +9% | +$925K | 0.01% | 1565 |
|
|
2019
Q1 | $10.3M | Sell |
120,173
-60,904
| -34% | -$5.06M | ﹤0.01% | 1683 |
|
|
2018
Q4 | $10.2M | Sell |
181,077
-52,551
| -22% | -$3.21M | 0.01% | 1591 |
|
|
2018
Q3 | $19.1M | Sell |
233,628
-173,095
| -43% | -$12.2M | 0.01% | 1342 |
|
|
2018
Q2 | $14.2M | Buy |
406,723
+375,446
| +1,200% | +$11.4M | 0.01% | 1443 |
|
|
2018
Q1 | $641K | Sell |
31,277
-322
| -1% | -$8.29K | ﹤0.01% | 3139 |
|
|
2017
Q4 | $895K | Sell |
31,599
-444
| -1% | -$12.4K | ﹤0.01% | 3024 |
|
|
2017
Q3 | $997K | Buy |
+32,043
| New | +$964K | ﹤0.01% | 2965 |
|
Other funds holding RETA
Ameriprise's RETA Position: Q3 2023 in Review
Ameriprise sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 89,771 shares — an estimated $9.15M sold.
Ameriprise first reported a position in RETA in Q3 2017 and held it in 21 quarters. The position peaked at $37.6M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Ameriprise reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Ameriprise sold 89,771 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $9.15M.
- Ameriprise first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 21 quarters.
- Ameriprise's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $37.6M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Ameriprise's 13F filing for Q3 2023, filed 14 Nov 2023.